Retreatment with icotinib in a patient with metastatic lung adenocarcinoma.

Abstract

A patient with advanced non-small cell lung cancer (NSCLC) was successfully treated with icotinib. The tumor relapsed after a partial response and the patient was retreated with icotinib after temporary cessation. Surprisingly we found that the tumor responded to icotinib again. The exact mechanism of this phenomenon is still unclear. A better understanding of the biological basis of involved events will help us to improve treatment of advanced NSCLC.

• Authors: Xiaoli Sun, Yulong Zheng
• Journal: Tumori (Tumori) 2013 May-Jun Vol. 99 Issue 3 Pg. e124-6 ISSN: 2038-2529 [Electronic] United States
• PMID: 24158081 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Crown Ethers
• Glutamates
• Protein Kinase Inhibitors
• Quinazolines
• Pemetrexed
• Guanine
• icotinib
• Carboplatin
• ErbB Receptors
• Protein-Tyrosine Kinases

Topics

• Adenocarcinoma (drug therapy, metabolism)
• Adenocarcinoma of Lung
• Antineoplastic Agents (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carboplatin (administration & dosage)
• Cranial Irradiation
• Crown Ethers (therapeutic use)
• ErbB Receptors (genetics, metabolism)
• Fatal Outcome
• Glutamates (administration & dosage)
• Guanine (administration & dosage, analogs & derivatives)
• Humans
• Lung Neoplasms (drug therapy, metabolism)
• Male
• Middle Aged
• Pemetrexed
• Protein Kinase Inhibitors (therapeutic use)
• Protein-Tyrosine Kinases (antagonists & inhibitors)
• Quinazolines (therapeutic use)
• Retreatment
• Salvage Therapy (methods)
• Tomography, X-Ray Computed